Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Myb overexpression synergizes with the loss of Pten and is a dependency factor and therapeutic target in T-cell lymphoblastic leukemia.
Almeida A, T'Sas S, Pagliaro L, Fijalkowski I, Sleeckx W, Van Steenberge H, Zamponi R, Lintermans B, Van Loocke W, Palhais B, Reekmans A, Bardelli V, Demoen L, Reunes L, Deforce D, Van Nieuwerburgh F, Kentsis A, Ntziachristos P, Van Roy N, De Moerloose B, Mecucci C, La Starza R, Roti G, Goossens S, Van Vlierberghe P, Pieters T. Almeida A, et al. Among authors: van roy n. Hemasphere. 2024 Mar 10;8(3):e51. doi: 10.1002/hem3.51. eCollection 2024 Mar. Hemasphere. 2024. PMID: 38463444 Free PMC article.
Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.
De Smedt R, Morscio J, Reunes L, Roels J, Bardelli V, Lintermans B, Van Loocke W, Almeida A, Cheung LC, Kotecha RS, Mansour MR, Uyttebroeck A, Vandenberghe P, La Starza R, Mecucci C, Lammens T, Van Roy N, De Moerloose B, Barata JT, Taghon T, Goossens S, Van Vlierberghe P. De Smedt R, et al. Among authors: van loocke w, van roy n, van vlierberghe p. Blood. 2020 May 7;135(19):1685-1695. doi: 10.1182/blood.2019003880. Blood. 2020. PMID: 32315407 Free article.
The epigenetic landscape of T-cell acute lymphoblastic leukemia.
Van der Meulen J, Van Roy N, Van Vlierberghe P, Speleman F. Van der Meulen J, et al. Among authors: van roy n, van vlierberghe p. Int J Biochem Cell Biol. 2014 Aug;53:547-57. doi: 10.1016/j.biocel.2014.04.015. Epub 2014 Apr 28. Int J Biochem Cell Biol. 2014. PMID: 24786297 Review.
Novel biological insights in T-cell acute lymphoblastic leukemia.
Durinck K, Goossens S, Peirs S, Wallaert A, Van Loocke W, Matthijssens F, Pieters T, Milani G, Lammens T, Rondou P, Van Roy N, De Moerloose B, Benoit Y, Haigh J, Speleman F, Poppe B, Van Vlierberghe P. Durinck K, et al. Among authors: van loocke w, van roy n, van vlierberghe p. Exp Hematol. 2015 Aug;43(8):625-39. doi: 10.1016/j.exphem.2015.05.017. Epub 2015 Jun 26. Exp Hematol. 2015. PMID: 26123366 Free article. Review.
Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia.
Ghazavi F, De Moerloose B, Van Loocke W, Wallaert A, Helsmoortel HH, Ferster A, Bakkus M, Plat G, Delabesse E, Uyttebroeck A, Van Nieuwerburgh F, Deforce D, Van Roy N, Speleman F, Benoit Y, Lammens T, Van Vlierberghe P. Ghazavi F, et al. Among authors: van nieuwerburgh f, van loocke w, van roy n, van vlierberghe p. Oncotarget. 2016 Nov 8;7(45):73769-73780. doi: 10.18632/oncotarget.12063. Oncotarget. 2016. PMID: 27650541 Free PMC article.
Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.
De Smedt R, Peirs S, Morscio J, Matthijssens F, Roels J, Reunes L, Lintermans B, Goossens S, Lammens T, Van Roy N, Touzart A, Jenni S, Tsai YC, Lovisa F, Mussolin L, Serafin V, Van Nieuwerburgh F, Deforce D, Uyttebroeck A, Tousseyn T, Burkhardt B, Klapper W, De Moerloose B, Benoit Y, Macintyre E, Bourquin JP, Basso G, Accordi B, Bornhauser B, Meijerink J, Vandenberghe P, Van Vlierberghe P. De Smedt R, et al. Among authors: van nieuwerburgh f, van roy n, van vlierberghe p. Haematologica. 2019 Jan;104(1):e17-e20. doi: 10.3324/haematol.2018.199257. Epub 2018 Aug 3. Haematologica. 2019. PMID: 30076176 Free PMC article. No abstract available.
Genetic characterization and therapeutic targeting of MYC-rearranged T cell acute lymphoblastic leukaemia.
Milani G, Matthijssens F, Van Loocke W, Durinck K, Roels J, Peirs S, Thénoz M, Pieters T, Reunes L, Lintermans B, Vandamme N, Lammens T, Van Roy N, Van Nieuwerburgh F, Deforce D, Schwab C, Raimondi S, Dalla Pozza L, Carroll AJ 3rd, De Moerloose B, Benoit Y, Goossens S, Berx G, Harrison CJ, Basso G, Cavé H, Sutton R, Asnafi V, Meijerink J, Mullighan C, Loh M, Van Vlierberghe P. Milani G, et al. Among authors: van nieuwerburgh f, van loocke w, van roy n, van vlierberghe p. Br J Haematol. 2019 Apr;185(1):169-174. doi: 10.1111/bjh.15425. Epub 2018 Jun 25. Br J Haematol. 2019. PMID: 29938777 Free PMC article. No abstract available.
PHF6 mutations in T-cell acute lymphoblastic leukemia.
Van Vlierberghe P, Palomero T, Khiabanian H, Van der Meulen J, Castillo M, Van Roy N, De Moerloose B, Philippé J, González-García S, Toribio ML, Taghon T, Zuurbier L, Cauwelier B, Harrison CJ, Schwab C, Pisecker M, Strehl S, Langerak AW, Gecz J, Sonneveld E, Pieters R, Paietta E, Rowe JM, Wiernik PH, Benoit Y, Soulier J, Poppe B, Yao X, Cordon-Cardo C, Meijerink J, Rabadan R, Speleman F, Ferrando A. Van Vlierberghe P, et al. Among authors: van der meulen j, van roy n. Nat Genet. 2010 Apr;42(4):338-42. doi: 10.1038/ng.542. Epub 2010 Mar 14. Nat Genet. 2010. PMID: 20228800 Free PMC article.
MicroRNA-128-3p is a novel oncomiR targeting PHF6 in T-cell acute lymphoblastic leukemia.
Mets E, Van Peer G, Van der Meulen J, Boice M, Taghon T, Goossens S, Mestdagh P, Benoit Y, De Moerloose B, Van Roy N, Poppe B, Vandesompele J, Wendel HG, Van Vlierberghe P, Speleman F, Rondou P. Mets E, et al. Among authors: van der meulen j, van peer g, van roy n, van vlierberghe p. Haematologica. 2014 Aug;99(8):1326-33. doi: 10.3324/haematol.2013.099515. Epub 2014 Jun 3. Haematologica. 2014. PMID: 24895337 Free PMC article.
207 results